hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06316466, orgStudyIdInfo id: QYFYWZLL28521, briefTitle: Lipoprotein a is an Independent Risk Factor for Overall Survival in Patients With Pancreatic Cancer: a Propensity Score Matching Analysis, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2024-01-30, completionDateStruct date: 2024-03-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: jingxue, class: OTHER, descriptionModule briefSummary: Background: This study aims to assess the prognostic significance of serum lipoprotein (a) \[Lp (a)\] levels on overall survival (OS) and progression free survival (PFS) in individuals diagnosed with pancreatic cancer through the utilization of propensity score matching (PSM).Methods: A retrospective analysis was conducted on the clinicopathological data of 364 patients diagnosed with pancreatic cancer at the Affiliated Hospital of Qingdao University from January 2019 to December 2022. The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups. We applied PSM analysis to minimize selection bias. The study compared OS and PFS between two groups by Kaplan-Meier method and analyzed differences using the log-rank test. Additionally, univariate and multivariate Cox-regression analyses were performed to identify prognostic factors among patients., conditionsModule conditions: Pancreatic Carcinoma; Lipoprotein a; Overall Survival; Prognosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 360, type: ESTIMATED, armsInterventionsModule interventions name: Lp(a), outcomesModule primaryOutcomes measure: OS, secondaryOutcomes measure: PFS, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Affiliated Hospital of Qingdao University, status: RECRUITING, city: Qingdao, state: Shandong, country: China, contacts name: Jinyue Liu, role: CONTACT, phone: 17854269227, email: liujinyue99@163.com, geoPoint lat: 36.06488, lon: 120.38042, hasResults: False
protocolSection identificationModule nctId: NCT06316453, orgStudyIdInfo id: PARADISE-PK-09-03-2024, briefTitle: Prospective Assessment of Atherosclerotic Cardiovascular Disease (ASCVD) Risk, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Advanced Education & Research Center, class: OTHER, collaborators name: University of Karachi, collaborators name: Pakistan Cardiac Society (Heart House), descriptionModule briefSummary: This study aims to conduct a 10-year follow-up to assess ASCVD risk in Pakistan among individuals aged 30 years and above without a known history of ASCVD. The focus will be on evaluating ASCVD risk over this specific 10-year timeframe. The study will also validate risk assessment scores for identifying high-risk individuals and examine the incidence rate of ASCVD events during long-term follow-up., conditionsModule conditions: Atherosclerotic Cardiovascular Diseases (ASCVD), designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 3513, type: ESTIMATED, armsInterventionsModule interventions name: Evaluating ASCVD risk over 10 and 30 year and lifetime, outcomesModule primaryOutcomes measure: 10-year ASCVD risk Categorization, primaryOutcomes measure: 30-year ASCVD risk Categorization, primaryOutcomes measure: Lifetime ASCVD risk evaluation, primaryOutcomes measure: Genetic Risk Assessment of ApoB, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Advanced Education Institute and Research Center, status: RECRUITING, city: Karachi, state: Sindh, zip: 75270, country: Pakistan, contacts name: Shamoon Noushad, role: CONTACT, phone: 03333549258, geoPoint lat: 24.8608, lon: 67.0104, hasResults: False
protocolSection identificationModule nctId: NCT06316440, orgStudyIdInfo id: noise and postoperative pain, briefTitle: Effect of Noise Isolation on the Incidence of Moderate to Severe Postoperative Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-12, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: The Second Affiliated Hospital of Chongqing Medical University, class: OTHER, collaborators name: The First Affiliated Hospital of Zhengzhou University, collaborators name: Shapingba People's Hospital of Chongqing University, collaborators name: Chongganng General Hospital, collaborators name: Wuhan University, collaborators name: Tongji Hospital, descriptionModule briefSummary: To investigate the effect of noise isolation during general anesthesia on the incidence of moderate to severe postoperative pain in patients undergoing major abdominal surgery. The aim of this study was to determine whether noise isolation can reduce the Incidence of moderate to severe postoperative pain and analgesic use., conditionsModule conditions: Postoperative Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Patients were randomly divided into intervention group（noise blocking） and control group（No noise blocking）, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 304, type: ESTIMATED, armsInterventionsModule interventions name: Wear noise-cancelling earphones, outcomesModule primaryOutcomes measure: The incidence of moderate to severe postoperative pain, secondaryOutcomes measure: Patient controlled analgesia pump analgesic consumption, secondaryOutcomes measure: Patient controlled analgesia pump analgesic consumption, secondaryOutcomes measure: The incidence of additional analgesic requirements, secondaryOutcomes measure: Maximum pain score (NRS score) at 0-48 hours postoperatively, secondaryOutcomes measure: The incidence of moderate to severe postoperative pain, secondaryOutcomes measure: Accumulative postoperative pain NRS, otherOutcomes measure: Pain score (NRS score) at 0-6 hours postoperatively, otherOutcomes measure: Pain score (NRS score) at 6-12 hours postoperatively, otherOutcomes measure: Pain score (NRS score) at 12-24 hours postoperatively, otherOutcomes measure: Pain score (NRS score) at 24-48 hours postoperatively, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Anesthesiology, The Second Affiliated Hospital, Chongqing Medical University, status: RECRUITING, city: Chongqing, state: Chongqing, zip: 400010, country: China, contacts name: Guangyou Duan, MD, role: CONTACT, phone: (+86)18323376014, email: duangy@hospital.cqmu.edu.cn, geoPoint lat: 29.56278, lon: 106.55278, hasResults: False
protocolSection identificationModule nctId: NCT06316414, orgStudyIdInfo id: 1501/17, briefTitle: Omalizumab in Severe Asthmatics With Food Allergy, acronym: OSAFA, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-01-01, primaryCompletionDateStruct date: 2023-03-31, completionDateStruct date: 2023-03-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Bambino Gesù Hospital and Research Institute, class: OTHER, descriptionModule briefSummary: A prospective assessment of the impact of Omalizumab in terms of efficacy, safety, and quality of life (FA-QoL) in patients with moderate/severe asthma and history of anaphylaxis to peanut, tree nuts, fish, egg, milk, and/or wheat. Evaluation of the trend of total and specific IgE during Omalizumab treatment., conditionsModule conditions: Food; Allergy, Anaphylactic Shock, conditions: Asthma in Children, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 65, type: ACTUAL, armsInterventionsModule interventions name: Omalizumab, outcomesModule primaryOutcomes measure: Milligram tolerated food allergen (gms) of raw and baked milk, raw and baked egg, hazelnut, peanut, wheat, and/or fish at T1., secondaryOutcomes measure: Proportion of negative OFCs at T1, secondaryOutcomes measure: NOAEL for raw and baked milk, raw and baked egg, hazelnut, peanut, wheat, and/or fish at T2., secondaryOutcomes measure: NOAEL for raw and baked milk, raw and baked egg, hazelnut, peanut, wheat, and/or fish at T3., secondaryOutcomes measure: Change in number of anaphylactic events, secondaryOutcomes measure: Rate of severity of anaphylactic events, secondaryOutcomes measure: Asthma Control Test (ACT), secondaryOutcomes measure: Quality of Life score, secondaryOutcomes measure: Total IgE, secondaryOutcomes measure: Specific IgE for milk, egg, hazelnut, peanut, wheat, and/or fish, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Pediatric Hospital Bambino Gesù IRCCS - Allergy Dpt, city: Roma, zip: 00145, country: Italy, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06316401, orgStudyIdInfo id: 03-2024, briefTitle: Endoscopic Submucosal Dissection of Large Recto-sigmoid Lesions Under Spinal Anesthesia, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-01-01, primaryCompletionDateStruct date: 2023-01-31, completionDateStruct date: 2024-03-03, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Azienda USL Modena, class: OTHER, descriptionModule briefSummary: The investigators collected data on all consecutive patients who underwent ESD for recto-sigmoid laterally spreading tumors (LSTs) \>35 mm under SA between January 2021 and March 2024. The investigators evaluated the technical success and safety of SA in terms of ARAEs, and pain, measured via visual assessment scale (VAS)., conditionsModule conditions: Colorectal (Colon or Rectal) Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 20, type: ACTUAL, armsInterventionsModule interventions name: ESD of large LSTs under SA, outcomesModule primaryOutcomes measure: Technical success of ESD under SA, primaryOutcomes measure: Safety of ESD under SA, secondaryOutcomes measure: Intra- and post-procedural need for additional opioid or other analgesic drug administration, secondaryOutcomes measure: ESD- and colonoscopy-related AEs, secondaryOutcomes measure: Length of hospital stay, secondaryOutcomes measure: Median ESD duration, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mauro Manno, city: Carpi, state: MO, zip: 41012, country: Italy, geoPoint lat: 44.78237, lon: 10.8777, hasResults: False
protocolSection identificationModule nctId: NCT06316388, orgStudyIdInfo id: TDME, briefTitle: Outcomes After Vitrectomy in Eyes With Tractional Diabetic Macular Edema, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-10, primaryCompletionDateStruct date: 2025-03-10, completionDateStruct date: 2025-03-11, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Rehab Azzam, class: OTHER, descriptionModule briefSummary: 1. assessment the outcomes of vitrectomy on retinal function by mf-ERG (multifocal electroretinogram) and anatomy by OCT (optical coherence tomography) in patients with tractional diabetic macular edema (TDME) .2. To correlate the postoperative corrected distance visual acuity (CDVA) with the mf-ERG and OCT findings following vitrectomy surgery for TDME., conditionsModule conditions: Diabetic Macular Edema, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 21, type: ESTIMATED, armsInterventionsModule interventions name: vitrectomy, outcomesModule primaryOutcomes measure: assessment the outcomes of vitrectomy on retinal function in patients with tractional diabetic macular edema, primaryOutcomes measure: assessment the outcomes of vitrectomy on retinal anatomy in patients with tractional diabetic macular edema, secondaryOutcomes measure: correlation CDVA with mf-ERG and OCT finding, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06316375, orgStudyIdInfo id: STUMBL blunt chest trauma, briefTitle: STUMBL Score as a Risk Stratification Tool for Management of Blunt Chest Trauma Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2026-04-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: The aim of this study is to assess validity of the STUMBL score in EGYPT for complications of blunt chest trauma without multi-trauma and immediate life-threatening injuries and identify patients at risk of in- hospital mortality or ICU admission and predict survival in both Assiut \& Suez Canal University Hospitals., conditionsModule conditions: Blunt Injury of Thorax, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, outcomesModule primaryOutcomes measure: The primary outcome was to assess the validity of the STUMBL score for all complications of chest blunt trauma, originally defined by the STUMBL authors, secondaryOutcomes measure: Secondary outcomes validated the STUMBL score using a composite of early and delayed complications., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06316362, orgStudyIdInfo id: SMOF in carbamazepine toxicity, briefTitle: Efficacy of SMOF Lipid in the Management of Acute Poisoning With Carbamazepine, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-01, primaryCompletionDateStruct date: 2023-02-01, completionDateStruct date: 2023-02-28, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Alexandria University, class: OTHER, descriptionModule briefSummary: The goal of the current study was to evaluate whether SMOF lipid administration could be used as an adjuvant therapy to treat acute, moderate-to-severe carbamazepine poisoning., conditionsModule conditions: Acute Poisoning, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: SMOF lipid 20%, outcomesModule primaryOutcomes measure: Improvement in Conscious Levels Measured by Glasgow Coma Scale (GCS), secondaryOutcomes measure: Assessment of Intubation Requirement Using GCS and APACHE, secondaryOutcomes measure: Length of Intensive Care Unit (ICU) Stay, secondaryOutcomes measure: length of hospital stay, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 54 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Medicine, city: Alexandria, country: Egypt, geoPoint lat: 31.21564, lon: 29.95527, hasResults: False
protocolSection identificationModule nctId: NCT06316336, orgStudyIdInfo id: BE24-005, briefTitle: Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions, acronym: BE24-005, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-10, primaryCompletionDateStruct date: 2024-06-22, completionDateStruct date: 2024-06-28, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Pharma Nueva, class: INDUSTRY, descriptionModule briefSummary: Objectives:To determine and compare the rate and extent of absorption of a test formulation with that of a reference innovator formulation when given as equal labeled dose after multiple oral dose administration in healthy subjects under fed conditions and To evaluate safety of test and reference formulationsStudy Design:An open label, randomized, two-treatment, two-period, two-sequence, multiple oral dose, crossover bioequivalence study in healthy Thai male volunteers under fed conditions with at least 7 days washout period between last dosing of Period 1 and first dosing of Period 2., conditionsModule conditions: Healthy Vollunteer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 44, type: ESTIMATED, armsInterventionsModule interventions name: Alfuzosin Hydrochloride 10 mg, interventions name: Xatral® XL 10 mg, outcomesModule primaryOutcomes measure: Plasma area Under the Curve (AUC(Day 6 and Day 7)) for Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets, primaryOutcomes measure: Peak Plasma Concentration (Cmax) of Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06316310, orgStudyIdInfo id: XSF20240312, briefTitle: Effect of Acupoint Thread Embedding on Obesity, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Shanghai Municipal Hospital of Traditional Chinese Medicine, class: OTHER, descriptionModule briefSummary: The investigators describe a protocol for a randomized controlled trial to find out the effect and safety of acupoint thread embedding on losing weight in obese patients., conditionsModule conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: All eligible participants will be randomly assigned into two group at a ratio of 1:1, the Acupoint Thread Embedding group and the Sham Acupoint Thread Embedding group (the control group).group)., primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 110, type: ESTIMATED, armsInterventionsModule interventions name: acupoint thread embedding, outcomesModule primaryOutcomes measure: Body Mass Index (BMI), secondaryOutcomes measure: Change in body weight, secondaryOutcomes measure: Changes in body circumference, secondaryOutcomes measure: Body composition analysis, secondaryOutcomes measure: Abdominal visceral fat tissue thickness, secondaryOutcomes measure: Fasting blood glucose (FPG), secondaryOutcomes measure: Blood lipid profile, secondaryOutcomes measure: Impact of Weight on Quality-of-Life Scale (IWQOL-Lite), secondaryOutcomes measure: Well-Being Index (WHO-5), secondaryOutcomes measure: Visual analog scale (VAS) of appetite, secondaryOutcomes measure: Hamilton Anxiety Scale (HAMA), secondaryOutcomes measure: Adverse effects, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Shanghai Municipal Hospital of Traditional Chinese Medicine, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200071, country: China, contacts name: Shifen Xu, PhD, role: CONTACT, phone: +8613761931393, email: xu_teacher2006@126.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06316284, orgStudyIdInfo id: miRNA-CKD, briefTitle: miRNA in Chronic Kidney Diseases, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Josip Juraj Strossmayer University of Osijek, class: OTHER, collaborators name: University Hospital Center Osijek, descriptionModule briefSummary: Oxidative stress and endoplasmic reticulum (ER) stress play a key role in tubular damage in both acute kidney injury and chronic kidney disease (CKD). Oxidative stress in the kidneys promotes renal vascular remodeling and increases preglomerular resistance. These are key elements in hypertension, acute and chronic kidney injury, as well as diabetic nephropathy. Chronic renal hypoxia is highlighted as the final common pathway to end-stage renal disease (ESRD). MicroRNA molecules (miRNA) also play an important role in these processes. MicroRNAs (miRNAs) are regulators of gene expression and play a role in the progression of renal ischemia-reperfusion injury. Although the pathophysiological contribution of microRNAs (miRNAs) to kidney damage has also been highlighted, the effect of miRNAs on kidney damage under conditions of oxidative and ER stress remains understudied., conditionsModule conditions: Chronic Kidney Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Systemic microvascular function, primaryOutcomes measure: Serum level of antixidant enzymesprotein concentration of SOD, CAT and glutathione-peroxidase, primaryOutcomes measure: Detecton of miRNA of interest, secondaryOutcomes measure: Body fluid compartments, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 69 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of Medicine Osijek, city: Osijek, zip: 31000, country: Croatia, geoPoint lat: 45.55111, lon: 18.69389, hasResults: False